Call it a sad commentary on the state of the medical imaging market: Fidelity Medical hasexited the industry in favor of greener pastures in retail stationery.The Florham Park, NJ, company this month announced that it hassold its x-ray digitization
Call it a sad commentary on the state of the medical imaging market: Fidelity Medical hasexited the industry in favor of greener pastures in retail stationery.The Florham Park, NJ, company this month announced that it hassold its x-ray digitization business to Chester Holdings Ltd.in a transaction valued at $900,000.
Fidelity has had a rough time in the industry since 1992, whenthen-CEO Efraim Landa left the firm after revealing that the company'sbalance sheet had been inflated (SCAN 8/26/92).
Fidelity hired former Siemens executive Werner Haas in an effortto turn the company around. Red ink continued to flow from thefirm, however, and a shareholder lawsuit related to the bogusfinancial results dogged the company. Fidelity posted a net lossof $5 million in 1992, a net loss of $10.1 million in 1993 anda net loss of $1.9 million last year. Fidelity postponed the filingof its 1994 results for several months due to doubts about thecompany's future (SCAN 3/1/95 and 2/1/95).
Fidelity began divesting its businesses in 1993, when it soldan unprofitable Israeli subsidiary. It shifted its focus awayfrom medical imaging when it bought U.K. stationery retailer CornicheDistribution last month (SCAN 4/12/95).
Fidelity completed its exit from radiology this month whenit sold all of its stock in medical imaging products in exchangefor 2.2 million shares of Fidelity common stock acquired by Chesterin connection with the Corniche acquisition. Fidelity also receiveda 180-day promissory note for $200,000.
Fidelity's new chairman, Brian Baylis, said the company madethe move to exit a business where it had been generating yearsof losses.
"Fidelity's board of directors believes that Fidelity'sfuture lies outside (medical imaging)," Baylis said. "Thedisposition of the medical imaging products business will allowFidelity to focus its attention and resources on the developmentand expansion of its stationery operations."
SNMMI: Can Multimodal Monitoring Bolster Outcomes with Pluvicto in Treating mCRPC?
June 22nd 2025Multimodal treatment monitoring, including SPECT/CT exams 24 hours after treatment with Lu-177 PSMA-617, may have facilitated significantly shorter therapy durations and reduced side effects in patients with mCRPC, according to a two-year study presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
Can CT-Based Deep Learning Bolster Prognostic Assessments of Ground-Glass Nodules?
June 19th 2025Emerging research shows that a multiple time-series deep learning model assessment of CT images provides 20 percent higher sensitivity than a delta radiomic model and 56 percent higher sensitivity than a clinical model for prognostic evaluation of ground-glass nodules.
Where Things Stand with the Radiologist Shortage
June 18th 2025A new report conveys the cumulative impact of ongoing challenges with radiologist residency positions, reimbursement, post-COVID-19 attrition rates and the aging of the population upon the persistent shortage of radiologists in the United States.